Stock Events

Stock Events

Damora Therapeutics 

$25.36
36
+$2.79+12.36% Friday 20:00
+$0.20+0.79%Friday 23:48After hours

Statistics

Day High
25.34
Day Low
25.16
52W High
38.33
52W Low
2.45
Volume
76,291
Avg. Volume
-
Mkt Cap
33.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q3 2025
Q1 2026
Next
-2.36
-1.7
-1.05
-0.39
Expected EPS
-0.42473
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-42.88MNet Income

Analyst Ratings

42.43Average Price Target
The highest estimate is 46.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DMRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.7B
Madrigal Pharmaceuticals is involved in developing therapies for fibrosis, particularly NASH, a direct area of competition with Galecto.
Lakefront Biotherapeutics NV
GLPG
Mkt Cap1.86B
Galapagos NV specializes in drug discovery for fibrosis and other indications, overlapping with Galecto's research areas.
ProQR Therapeutics N.V
PRQR
Mkt Cap199.14M
ProQR Therapeutics works on treatments for fibrosis among other diseases, positioning it as a competitor in the fibrosis space.
Gilead Sciences
GILD
Mkt Cap158.77B
Gilead Sciences has a strong portfolio in treating fibrotic diseases, making it a major competitor to Galecto.
Vertex Pharmaceuticals
VRTX
Mkt Cap124.7B
Vertex Pharmaceuticals has expanded its focus to include fibrosis, directly competing with Galecto's pipeline.
Pfizer
PFE
Mkt Cap138.44B
Pfizer has a broad range of treatments including for fibrosis, positioning it as a competitor across multiple areas including those targeted by Galecto.
Abbvie
ABBV
Mkt Cap447.62B
AbbVie has research interests in fibrosis, making it a competitor in the therapeutic area Galecto is targeting.
Novartis
NVS
Mkt Cap296.54B
Novartis has a diversified portfolio that includes treatments for fibrosis, competing with Galecto in the fibrosis therapeutic area.

About

Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Show more...
CEO
Mr. Garrett Winslow Esq.
Employees
7
Country
United States
ISIN
US36322Q2066

Listings

XNAS
US
GLTO
BOATS
BOATS
GLTO.BOATS
XNAS
US
DMRA

0 Comments

Share your thoughts

FAQ

What is Damora Therapeutics stock price today?▼
The current price of DMRA is $25.36 USD — it has increased by +12.36% in the past 24 hours. Watch Damora Therapeutics stock price performance more closely on the chart.
What is Damora Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Damora Therapeutics stocks are traded under the ticker DMRA.
What is Damora Therapeutics market cap?▼
Today Damora Therapeutics has the market capitalization of 33.65M
When is the next Damora Therapeutics earnings date?▼
Damora Therapeutics is going to release the next earnings report on August 05, 2026.
What were Damora Therapeutics earnings last quarter?▼
DMRA earnings for the last quarter are -0.62 USD per share, whereas the estimation was -0.39 USD resulting in a -59.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Damora Therapeutics revenue for the last year?▼
Damora Therapeutics revenue for the last year amounts to 0 USD.
What is Damora Therapeutics net income for the last year?▼
DMRA net income for the last year is -42.88M USD.
How many employees does Damora Therapeutics have?▼
As of June 29, 2026, the company has 7 employees.
In which sector is Damora Therapeutics located?▼
Damora Therapeutics operates in the Other sector.
When did Damora Therapeutics complete a stock split?▼
The last stock split for Damora Therapeutics was on August 30, 2024 with a ratio of 1:25.
Where is Damora Therapeutics headquartered?▼
Damora Therapeutics is headquartered in Waltham, United States.